Trust Point Inc. Has $599,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Trust Point Inc. raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 45.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,697 shares of the biotechnology company’s stock after buying an additional 531 shares during the quarter. Trust Point Inc.’s holdings in United Therapeutics were worth $599,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Creative Planning grew its position in United Therapeutics by 20.1% in the 2nd quarter. Creative Planning now owns 3,613 shares of the biotechnology company’s stock worth $1,151,000 after purchasing an additional 605 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its stake in United Therapeutics by 10.2% during the second quarter. B. Riley Wealth Advisors Inc. now owns 1,067 shares of the biotechnology company’s stock valued at $340,000 after acquiring an additional 99 shares during the period. Cetera Investment Advisers raised its holdings in United Therapeutics by 8.7% in the 2nd quarter. Cetera Investment Advisers now owns 6,167 shares of the biotechnology company’s stock valued at $1,964,000 after acquiring an additional 493 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of United Therapeutics by 66.1% in the 3rd quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company’s stock worth $535,000 after acquiring an additional 594 shares during the period. Finally, Park Avenue Securities LLC grew its holdings in shares of United Therapeutics by 8.3% during the 3rd quarter. Park Avenue Securities LLC now owns 2,207 shares of the biotechnology company’s stock worth $791,000 after purchasing an additional 170 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on UTHR. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. TD Cowen raised their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $378.36.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $911,330.28. This represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the sale, the director now directly owns 5,655 shares of the company’s stock, valued at approximately $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 143,838 shares of company stock worth $53,981,956. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 0.3 %

United Therapeutics stock opened at $353.43 on Wednesday. The business’s 50-day simple moving average is $364.28 and its 200 day simple moving average is $357.68. The stock has a market cap of $15.78 billion, a price-to-earnings ratio of 15.52, a P/E/G ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.